K. Scott

发表

Spontaneous Clearance Of Vertically Acquired Hepatitis C Infection: Implications For Testing And Treatment.

A. Ades, D. Gibb, K. Butler, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of vitamin D supplements during infancy in an international feeding trial

C. de Beaufort, H. Siljander, V. Tillmann, 2013, Public Health Nutrition.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine

A. Ades, Y. Yazdanpanah, A. Mostafa, 2023, Journal of hepatology.

Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk

C. de Beaufort, H. Siljander, A. Hämäläinen, 2021, Diabetologia.

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.

T. Rhodes, N. Klein, D. Gibb, 2016, Health technology assessment.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

A. Winston, M. Johnson, M. Gompels, 2015, The lancet. HIV.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2016, The lancet. HIV.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

THREE-YEAR PROSPECTIVE STUDY OF HTLV-III/LAV INFECTION IN HOMOSEXUAL MEN

D. Jeffries, J. Weber, E. Berrie, 1986, The Lancet.

Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission

A. Ades, D. Gibb, K. Butler, 2021, medRxiv.

Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment

D. Gibb, K. Butler, C. Thorne, 2021, medRxiv.

Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial

C. de Beaufort, H. Siljander, V. Tillmann, 2017, Maternal & child nutrition.

Acceptability of HCV screening and potential use of DAAs during pregnancy in women attending antenatal care in Egypt, Pakistan and Ukraine

A. Mostafa, S. Hamid, D. Gibb, 2021, medRxiv.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2018, PloS one.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinic

J. Blackstone, E. Williams, C. Giaquinto, 2023, EClinicalMedicine.

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

J. Ainsworth, M. Gompels, A. Arenas-Pinto, 2024, EClinicalMedicine.